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Goenka et al. demonstrate that the SARS-
CoV-2 immune response of young infants
appears distinct compared with their
parents. They show that infants exhibit
relatively high serum (and saliva) levels of
anti-spike IgG associated with robust
SARS-CoV-2 neutralization but restrained
cellular spike-specific IFN-g production.ll
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Severe COVID-19 appears rare in children. This is unexpected, especially in young infants, who are vulnerable
to severe disease caused by other respiratory viruses. We evaluate convalescent immune responses in 4 in-
fants under 3 months old with confirmed COVID-19 who presented with mild febrile illness, alongside their
parents, and adult controls recovered from confirmed COVID-19. Although not statistically significant,
compared to seropositive adults, infants have high serum levels of IgG and IgA to SARS-CoV-2 spike protein,
with a corresponding functional ability to block SARS-CoV-2 cellular entry. Infants also exhibit robust saliva
anti-spike IgG and IgA responses. Spike-specific IFN-g production by infant peripheral blood mononuclear
cells appears restrained, but the frequency of spike-specific IFN-g- and/or TNF-a-producing T cells is com-
parable between infants and adults. On principal-component analysis, infant immune responses appear
distinct from their parents. Robust functional antibody responses alongside restrained IFN-g production
may help protect infants from severe COVID-19.
INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic is respon-
sible for unprecedented morbidity and mortality, particularly in
the elderly, but significant disease appears rare in children.1
Compared with older children, severe COVID-19 has been re-
ported relatively more commonly in young infants.1 Despite
this, approximately one-fourth of young infants infected with se-
vere acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)
are asymptomatic and there have been few reported deaths in
this age group.2 This is unexpected, given that early life is a
period of rapid transition for the immune system that renders in-
fants vulnerable to severe respiratory viral infections such as
those caused by respiratory syncytial virus and influenza.3,4
Few data are available describing SARS-CoV-2 immunity in in-
fants younger than 3 months old. We therefore evaluated anti-
body and cellular immune responses in a small cohort of young
infants recovered from COVID-19.
RESULTS AND DISCUSSION
Four infants younger than 12 weeks old presented with fever
without an obvious clinical focus to Bristol Royal Hospital for
Children (Bristol, UK) over a 4-week period in March 2020.
Baseline characteristics of the infants (I1–I4), their mothers
(M1–M4), and their fathers (F1–F4) are shown in Table 1. All of
Cell Reports Medicine 2, 100327, July 20, 2021 ª 2021 The Author(s). 1
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Please cite this article in press as: Goenka et al., Young infants exhibit robust functional antibody responses and restrained IFN-g production to SARS-
CoV-2, Cell Reports Medicine (2021), https://doi.org/10.1016/j.xcrm.2021.100327
ll
OPEN ACCESS
the parents experienced COVID-19 symptoms in the days pre-
ceding the development of symptoms in their infants, except for
2 fathers (F3 and F4), who remained asymptomatic. Themedian
age of the infants at presentation was 7 weeks (I1, 6 weeks; I2,
1 week; I3, 11 weeks corrected age; I4, 7 weeks). One infant
was exclusively breastfed (I2), 1 was exclusively formula fed
(I3), and 2 were mixed formula fed and breastfed (I1 and I4).
There was no significant perinatal or medical history, except
in 1 infant (I3) who was born at 28 weeks’ gestation and did
not suffer significant complications of prematurity but had
been recently admitted to the hospital with rhinovirus bronchio-
litis. Reduced peripheral lymphocyte counts of 1.2–2.13 109/L
cells/mm3 (normal range 3.3–10.3 3 109/L cells/mm3) were
observed in 2 infants (I1 and I2) but were normal in 1 infant
(I4) and not measured in 1 infant (I3). C-reactive protein was
measured in 3 infants (I1, I2, and I4) and was <1 mg/L (normal
range <5 mg/L) in all these infants alkl. A transiently raised
serum alanine aminotransferase with a peak of 207 U/L (normal
range <33 U/L) was observed in 1 infant (I1). SARS-CoV-2
quantitative reverse transcription-polymerase chain reaction
(qRT-PCR) was positive on nasopharyngeal swab in all 4 in-
fants, with a median (range) cycle threshold value of 24.4
(22.0–29.9). Empirical treatment with intravenous antibiotics
was commenced in 2 infants and discontinued at 36 h after
negative blood and urine culture in 1 infant (I1), and after
14 days in the other (I2), from whom group B streptococcus
was isolated from urine but not blood culture. None of the in-
fants required oxygen therapy or feeding support and all of
them exhibited symptom resolution within 2 days. Following re-
covery, peripheral blood and saliva were obtained for immuno-
logical analyses at a similar median interval after the onset of
COVID-19 symptoms from infants (78 days), parents
(66 days), and matched adult controls (63 days) who had recov-
ered from qRT-PCR-proven COVID-19 (Table 1).
Human coronavirus infections typically result in the production
of antibodies after 11–20 days that can persist for many months,
some of which have neutralizing activity and correlate with pro-
tection against re-infection.5 As such, serological assays have
played a pivotal role in developing our understanding of adaptive
and potentially protective immune responses to SARS-CoV-2
infection. Infants have been shown to produce broadly neutral-
izing antibodies rapidly to some viral infections, including HIV,6
but typically generate lower systemic and mucosal antibody
titers to other respiratory infections compared with adults.7,8 In
this study, we measured antibody responses to SARS-CoV-2
antigens using the luciferase immunoprecipitation system
(LIPS) and an enzyme-linked immunosorbent assay (ELISA). All
4 infants exhibited robust serum immunoglobulin G (IgG) re-
sponses to the SARS-CoV-2 spike protein and its receptor-bind-
ing domain (RBD) (Figures 1A, 1B, and S1). Although infants’
serum concentrations of anti-spike/RBD IgG appeared higher
than those of their parents and qRT-PCR confirmed adult con-
trols, the difference was not statistically significant after adjust-
ment for multiple comparisons. Concentrations of serum IgG
directed against SARS-CoV-2 nucleoprotein were low but above
pre-pandemic levels for infants and their parents (Figures 1B and
S1). Serum antibodies to SARS-CoV-2 antigens were not de-
tected in the 2 asymptomatic parents. Relatively high serum
IgA responses to spike and RBD were detected in 3 of the 4 in-
fants (Figure S1). None of the infants and 6 of the parents/qRT-
PCR-confirmed adult controls had SARS-CoV-2 specific IgM
serum antibody titers clearly above those in pre-pandemic sera
(Figure S1). Infants also exhibited robust salivary anti-spike IgG
and IgA responses (Figures 1C and 1D). The infant IgA response
may reflect endogenous antibody production rather than acqui-
sition from maternal breast milk, because the exclusively for-
mula-fed infant (I3) exhibited relatively high IgA titers compared
with the more modest titers of the exclusively breastfed infant
(I2) (Figures 1D and S1). A virus neutralization assay confirmed
that the high anti-spike/RBD IgG titers in infant sera mirrored
their functional ability to block SARS-CoV-2 entry into cells (Fig-
ures 1E, 1F, and S2). This is consistent with other reports demon-
strating a direct relationship between high anti-spike/RBD titers
and functional antibody responses in adults.9 Thus, infants
mounted robust and functional systemic and mucosal antibody
responses to SARS-CoV-2 spike/RBD suggestive of clinically
protective immunity.10
Alongside antibodies, T cells directed against SARS-CoV-2
have been observed in convalescent individuals.11 Since inter-
feron-g (IFN-g) has a key function in antiviral cell-mediated
immunity,11 we measured its production by peripheral blood
mononuclear cells (PBMCs) stimulated with peptide pools span-
ning SARS-CoV-2 proteins using an enzyme-linked immunoab-
sorbent spot (ELISpot) assay (Figure S3A). Like others,11 we
observed a significant correlation (r = 0.82, p < 0.001) between
the concentration of serum anti-spike IgG and IFN-g production
by PBMCs in response to stimulation by spike peptide pools
among the seropositive adults recovered from COVID-19 (Fig-
ure S3B). Production of IFN-g by PBMCs from infants and par-
ents (alongside 4/5 PCR-proven adult COVID-19 controls) was
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Clinical features, n (%)
Asymptomatic 0 (0) 2 (25) 0 (0)
Fever 4 (100) 4 (50) 8 (80)
Cough 4 (100) 4 (50) 6 (60)
Coryza 4 (100) 1 (12.5) 3 (30)
Sore throat N/A 1 (12.5) 2 (20)
Loss taste/smell N/A 3 (37.5) 9 (90)
Gastrointestinal features 0 (0) 1 (12.5) 3 (30)
Symptoms >2 wk 0 (0) 2 (25) 4 (40)
Hospital admission,
n (%)
4 (100) 0 (0) 0 (0)
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Figure 1. Robust and functional antibody response to SARS-CoV-2 in young infants
(A) Serum anti-RBD IgGmeasured using luciferase immunoprecipitation system (LIPS) assay expressed in units (derived from a pooled internal serum standard).
(B) Serum anti-spike IgG and anti-nucleocapsid IgG titers measured by ELISA; background optical density (OD) at 620 nm was subtracted from signal OD at
492 nm and corrected for average blank wells.
(C and D) Saliva anti-spike IgG (C) and (D) saliva anti-spike IgA (right) measured by ELISA; background optical density (OD) at 570 nmwas subtracted from signal
OD at 450 nm.
(E) Serum neutralization of SARS-CoV-2 measured by infection of Vero E6 cells with SARS-CoV-2 pre-incubated with decreasing concentrations of serum from
infants (I1–I4), mothers (M1–M4), and fathers (F1–F4); adults recovered from RT-PCR confirmed COVID-19; and pre-pandemic sera, in which color intensity
represents neutralization (i.e., percentage of infected cells relative to control wells containing virus only [no sera]).
(F) Representative immunofluorescence images of assay described in (D) with 1:125 dilution of sera from an infant (I2), parent (M2), pooled sera from RT-PCR-
confirmed COVID-19 controls, and pre-pandemic samples, in which the nucleic acid of Vero E6 cells is stained by DAPI (blue) and SARS-CoV-2 is visualized with
anti-nucleocapsid antibody (Rockland, 200-401-A50) and an Alexa Fluor 568 conjugated secondary antibody. Images were acquired and analyzed using the
ImageXpress Pico system. Scale bar represents 500 mm.
(legend continued on next page)
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detected following stimulation with spike peptide pools (Fig-
ure 2A). The 2 asymptomatic parents exhibited IFN-g production
(Figure 2A), which has been described in seronegative individ-
uals andmay represent SARS-CoV-2 exposure or cross-reactive
T cell immunity from seasonal coronaviruses.12,13 To further
explore the antigen-specific cytokine production and its cellular
source in infants, we measured IFN-g and tumor necrosis factor
a (TNF-a) production by CD4+ and CD8+ T cells using flow
cytometric intracellular cytokine staining (ICS) following ex vivo
stimulation of PBMCs with peptide pools spanning SARS-
CoV-2 proteins (Figure S3C). Comparable frequencies of cyto-
kine positive CD4+ and CD8+ T cells (defined as IFN-g and/or
TNF-a+) were detectable among infants’ and parents’ PBMCs
following stimulation with spike and membrane/nucleocapsid
peptide pools (Figures 2B and 2C). Given the low magnitude of
infant cellular responses we observed ex vivo, compared with
relatively high infant anti-SARS-CoV-2 antibody titers, we sought
to determine their T cell antigen specificity by in vitro expansion
with SARS-CoV-2 peptide pools.14 Of the 3 infants from whom
we had a sufficient yield of PBMCs, all of them exhibited a signif-
icant expansion of CD4+ T cells reactive to peptide pools span-
ning spike as well as M/N protein pools, suggestive of antigen
specificity (Figures 2D–2F). Interestingly, infants’ PBMCs ap-
peared to exhibit a lower production of IFN-g in response to
spike protein compared with adults’ by both ELISpot (Figure 2A)
and ICS (Figures S3D and S3E), although the difference was not
statistically significant after adjustment for multiple compari-
sons. These apparent differences may be representative of the
well-documented and generalized decreased type 1 cytokine-
producing ability of infant T cells,15 which we also observed in
response to mitogen stimulation (Figure S3F). Assessed by prin-
cipal-component analysis, the antibody and cellular immune
response to SARS-CoV-2 in young infants collectively appeared
distinct from those of their parents, despite the lack of statistical
significance in individual assays after adjustment for multiple
comparisons (Figure 2G).
These data suggest that the mild clinical course of COVID-19
reported in young infants may be associated with robust func-
tional antibody responses and restrained IFN-g production.
Describing the molecular mechanisms underlying the mild
course of COVID-19 in infants during their period of vulnerability
to other severe respiratory viral infections and contrasting them
with those seen in severely affected adults may help explain the
pathogenesis of severe COVID-19.
LIMITATIONS OF THE STUDY
There are several limitations of our study. This is a small cohort
and participants underwent sampling at a single time point
only. As well as confirming our observations in a larger cohort
of participants, it would be valuable in future studies to study
both innate and adaptive responses in infants compared with
adults, in the acute phase of COVID-19 and by longitudinal ob-
servations in convalescence. The present study is also restricted
to individuals recovering from mildly symptomatic COVID-19,
therefore potentially not representative of the significant propor-
tion of young infants and adults with asymptomatic infection. In
addition, we were unable to assess the neutralizing capacity of
the mucosal antibody due to the low sample volume and had
insufficient PBMCs to definitively demonstrate their antigen
specificity by tetramer staining. Comparing infant and adult
T cell responses to a broader range of epitopes such as non-
structural SARS-CoV-2 peptides would be of interest in future
studies.11,13,14
STAR+METHODS
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Figure 2. Young infants exhibit distinct cellular and antibody immune responses to SARS-CoV-2
(A) IFN-g productionmeasured by ELISpot following 18-h ex vivo stimulation of PBMCswith SARS-CoV-2 spike (S1 and S2) peptide pools (2 mg/mL). Significance
determined by Kruskal-Wallis test with Bonferroni’s correction for multiple comparisons.
(B and C) Proportion of cytokine (TNF-a and/or IFN-g)-producing CD4+ and CD8+ T cells (naive CD45RA+ CCR7+ excluded) measured by intracellular cytokine
staining (ICS) of PBMCs following 5-h ex vivo stimulation with SARS-CoV-2 peptide pools spanning spike (S1/S2) or membrane/nucleocapsid protein (1 mg/mL).
Significance determined by Mann-Whitney U test.
(D) Proportion of cytokine-producingCD4+ T cellsmeasured by ICS following PBMCstimulation as described above (indicated as ‘‘Direct ex vivo’’) comparedwith
in vitro expansion of PBMCs pulsed with peptide pools (5 mg/mL) for 45 min, followed by 10-day culture in the presence of interleukin-2 (IL-2) (20 IU/mL) and then
re-stimulated for 5 h with SARS-CoV-2 peptide pools (indicated as ‘‘10-day expansion’’).
(E and F) Representative ICS plots of ‘‘Direct ex vivo’’ (E) and ‘‘10-day expansion’’ (F) samples from I2.
(G) Principal-component analysis incorporating data from assaysmeasuring serum anti-spike/RBD/nucleocapsid IgG/IgM/IgA and viral neutralization; saliva IgG/
IgA; IFN-g production by total PBMCs (ELISpot); cytokine (TNF-a and/or IFN-g)-positive CD4+ andCD8+ T cells (ICS) in infants and their parents; 95% confidence
ellipses shown.
Data points represent single observations (ICS) or means of technical duplicates (ELISpot) with unstimulated signal subtracted in both ELISpot and ICS assays.
Individual families denoted by color (1: red, 2: green, 3: blue, 4: orange); infants (colored circles), fathers (colored squares), mothers (colored square with central
marking); RT-PCR confirmed adult controls (black squares), pre-pandemic controls (clear squares).
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse anti-polyHistidine HRP conjugated antibody Sigma-Aldrich Cat#A7058; RRID: AB_258326
Goat anti-human IgG-HRP antibody Southern Biotech Cat#2040-05; RRID: AB_2795644
Goat anti-human IgA (a-chain-specific)-peroxidase antibody Sigma-Aldrich Cat#A0295; RRID: AB_257876
Goat anti-human IgM (m-chain-specific)-peroxidase antibody Sigma-Aldrich Cat#A6907; RRID: AB_258318
Goat anti-Rabbit, AlexaFluor 568 conjugated
secondary antibody
Thermo Fisher Scientific Cat#A-11011; RRID: AB_143157
Rabbit anti-SARS-CoV-2 nucleocapsid antibody Rockland Cat#200-401-A50; RRID: AB_828403
Mouse anti-human CD4 BV650 BioLegend Cat#300536; RRID: AB_2632791
Mouse anti-human CD8 APC/Cyanine7 BioLegend Cat#344714; RRID: AB_2044006
Mouse anti-human CCR7 PE/Cyanine7 BioLegend Cat#353226; RRID: AB_353226
Mouse anti-human CD3 AF700 BD Biosciences Cat#561027; RRID: AB_10561682
Mouse anti-human CD45RA BD Biosciences Cat# 555489; RRID: AB_395880
Mouse anti-human IFN-g V450 BD Biosciences Cat# 560371; RRID: AB_1645594
Mouse anti-human TNF-a PE/Dazzle 594 BioLegend Cat# 502946; RRID: AB_2564173
Bacterial and virus strains
SARS-CoV-2/human/Liverpool/REMRQ0001/2020 Dr Lance Turtle N/A
Biological samples
Human AB serum Merck KGaA Cat#H6914
Chemicals, peptides, and recombinant proteins
SARS-CoV-2 spike protein This paper N/A
SARS-CoV-2 Receptor Binding Domain (RBD) protein This paper N/A




1-Step Ultra TMB-ELISA Substrate Solution-1 L Thermo Fisher Cat#34029
Human recombinant IL-2 protein R&D Systems Cat#202-IL
Protein A Sepharose Cytiva Cat#17528003
Protein G Sepharose Cytiva Cat#17061806
Nano-Glo Promega Cat#N1150
N-terminally nanoluciferase tagged monomeric RBD Dr Vito Lampasona N/A
DAPI for nucleic acid staining Sigma-Aldrich Cat#D9542-1MG
SARS-CoV-2 spike protein overlapping
peptide library (custom made)
Mimotopes N/A
SARS-CoV-2 spike protein overlapping
peptide library (custom made)
Prof Tao Dong (Peng et al., 2020)11
PepTivator SARS-CoV-2 Prot_M-research grade Miltenyi Biotec Cat#130-126-702




Expi293 Expression System Thermo Fisher Scientific Cat#A14635
Human IFN-g ELISpotPLUS kit (ALP) strips Mabtech 3420-4AST-2
Zombie Aqua Fixable Viability Kit BioLegend Cat# 423102
OneComp eBeads Compensation Beads Thermo Fisher Scientific Cat#01-1111-42
(Continued on next page)
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Anu
Goenka (anu.goenka@bristol.ac.uk).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The datasets generated during this study have been uploaded to https://data.mendeley.com at https://dx.doi.org/10.17632/
v78gcvxc2s.3
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects and samples
Clinical information and blood/saliva samples were obtained under research ethics approval of the Bristol Biobank (NHSREC 14/WA/
1253). Written informed consent was obtained from parents and adult control cases. Information regarding donor demographics can
be found in Table 1. Pre-pandemic adult serum samples were also obtained from the Bristol Biobank and were used as controls for
the serology assays. Blood was collected by venepuncture into EDTA tubes (BD Biosciences) for PBMC isolation by Ficoll gradient
[using Leucosep tubes (Greiner Bio-One) when blood volume was sufficient], and SST tubes (BD Sciences) for serum; PBMC and
serum samples were stored in liquid nitrogen or at 70C, respectively, until further use. Serum samples were heat inactivated
for 30 minutes at 56C prior to their use in the assays. Pre-pandemic saliva was collected from adults on a sterile sponge (Malvern
Medical Developments) as previously described.16 Saliva samples were collected from adult study participants into a funnel over a
collection tube (Isohelix). Saliva was collected from infants using a sterile oral swab (Iskus Health). Some assays could not be per-
formed on all participants because of the limited blood/saliva volumes available.
Cell lines
Vero E6 cells (ATCC) and Vero E6 cells engineered to express the cell surface protease TMPRSS2 (Vero-TMPRSS2) (National Insti-
tute for Biological Standards and Control) were cultured at 37C in 5% CO2 in Dulbecco’s Modified Eagle’s medium containing
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental models: cell lines
Vero E6 ATCC ATCC CRL-1586; RRID: CVCL_0574
VeroE6/TMPRSS2 NIBSC Repository reference: 100978;
RRID: CVCL_YQ49
Recombinant DNA
pFastBacDual spike Prof Florian Krammer N/A
pFastBac Dual RBD Prof Florian Krammer N/A
pET28a-NP-FL Prof Ashley Toye N/A
pCMV-TnT RBD Dr Vito Lampasona N/A
Software and algorithms




FlowJo V10.7.1 Tree Star, Inc https://www.flowjo.com; RRID: SCR_008520
GraphPad Prism V9.0 GraphPad https://www.graphpad.com/scientific-
software/prism/; RRID: SCR_002798
R, V 4.0.2 The R Foundation for
Statistical Computing
https://www.r-project.org/
R studio, V 1.2.1073 RStudio https://www.rstudio.com/
Factoextra, V1.0.7 CRAN https://cran.r-project.org/web/packages/
factoextra/index.html; RRID:SCR_016692
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GlutaMAX (Thermo Fisher Scientific) supplemented with 10% fetal calf serum (FCS) (Thermo Fisher Scientific) and 0.1 mM non-
essential amino acids (NEAA) (Sigma Aldrich).
METHOD DETAILS
Protein production for ELISA
SARS-CoV-2 trimeric spike protein ectodomain and receptor binding domain (RBD) were produced in insect cells as previously
described.17 SARS-CoV-2 spike ectodomain was expressed in insect cells with pFastBac Dual (Thermo Fisher Scientific) plasmid
as previously described,18 a gift from Florian Krammer (Icahn School of Medicine, USA). This construct of spike contains amino acids
1 to 1213 and with a C-terminal thrombin cleavage site, a T4-foldon trimerization domain followed by a hexahistidine tag for affinity
purification. In this construct, polybasic cleavage site has been removed (RRAR to A).18 pFastBac Dual plasmid for insect cell expres-
sion of SARS-CoV-2 RBDwas also a gift from Florian Krammer. This construct is comprised of spike amino acid 319 to 541, preceded
at N terminus with the secretion signal sequence of native spike (MFVFLVLLPLVSSQ) and followed by a c-terminal octa-histidine tag
for purification. For both spike and RBD,MultiBac baculovirus expression systemwas used to produce the proteins in Hi5 insect cells
as previously described.19 A similar purification protocol was used for both spike and RBD. Three days after infection, cell cultures
expressing the spike or RBD protein were centrifuged at 1,000 g for 10min to collect the media with secreted protein as supernatant,
which was again centrifuged at 5,000 g for 30 min. This media was then incubated with 7 mL (10 mL for RBD) HisPur Ni-NTA Super-
flow Agarose (Thermo Fisher Scientific) for each 3 L of expression for 1 hour at 4C. Next, Ni-NTA resin bound with spike or RBD was
collected using a gravity flow column, followed by extensive wash with 15 column volume wash buffer (65 mM NaH2PO4, 300 mM
NaCl, 20mM imidazole, pH 7.5). Finally, a step gradient of elution buffer (65mMNaH2PO4, 300mMNaCl, 235mM imidazole, pH 7.5)
was used to elute the protein. Elution fractions were analyzed by reducing SDS-PAGE. Fractions containing spike or RBD were
pooled and concentrated using 50 kDa MWCO Amicon centrifugal filter units (EMD Millipore) and then finally buffer-exchanged in
phosphate-buffered saline (PBS) pH 7.5 before aliquoting and flash freezing in liquid nitrogen. Samples were stored at 80C until
further use.
A codon-optimized, N-terminal His6 tagged full length nucleocapsid protein of SARS-CoV-2 was synthesized and cloned by
GenScript into a pET28a bacterial expression plasmid, (called here pET28a-NP-FL). The pET28a-NP-FL plasmid was transformed
into E. coli strain BL21 (DE3). Protein expression was induced by the addition of 1 mM IPTG and then incubated overnight at
20C. Cells were pelleted by centrifugation and resuspended in 20 mM Tris pH 8, 500mM NaCl, 10 mM imidazole, 1 mM NaF and
1mMPMSF. Cells were lysed by passage through a French Press (Spectronic Instruments) and the resulting lysateswere centrifuged
at 39,000 g at 4C for 30min. The supernatant was applied to a HisTrap HP nickel affinity column (GEHealthcare) andwashed using a
series of wash buffers containing 10-40 mM Imidazole (20 mM Tris pH 8, 500 mMNaCl, containing 10, 20 and 40mM Imidazole). The
protein was eluted in 20 mM Tris pH 8, 500 mM NaCl and 500 mM imidazole and further purified by size exclusion chromatography
using a HiLoad 16/600 Superdex 200 pg column (GE Healthcare) equilibrated and eluted in 20 mM Tris pH 8 and 500 mMNaCl. Peak
fractions were pooled and concentrated in a 10 kDa MWCO Vivaspin ultrafiltration unit. Protein concentration was determined using
the Bradford assay. Typical yields of N proteins after Ni-NTA and size exclusion chromatography was approximately 9 mg/L. Purified
proteins were analyzed by SDS-PAGE and by Western-blot using an anti-his tag antibody (Sigma).
Serum ELISA
Serum antibodies specific for SARS-CoV-2 spike protein, RBD and the nucleocapsid protein were detected by an ELISA based on
described methodology.18 Spike, RBD and nucleocapsid were each diluted in sterile PBS (Sigma) andMaxiSorp plates (NUNC) were
coated with either 10 mg/ml (spike) or 20 mg/ml (RBD; nucleocapsid protein) of protein overnight at 4C before use. Plates were
blocked with a 1-hour incubation in 3% Bovine Serum Albumin (BSA) (Sigma-Aldrich) in PBS with 0.1% Tween-20 (Sigma-Aldrich)
(PBS-T) at room temperature. Serum samples were thawed before use, tested in duplicate and diluted to a final volume of 100 ml per
well at a pre-optimized dilution, either at 1 in 50 (PanIg, IgA, IgM assays) or 1 in 450 dilution (IgG assay), in dilution buffer (1% BSA in
PBS-T) and all samples tested on a single plate for each antigen and antibody isotype combination. Secondary antibodies were used
as follows with the dilution factor indicated: HRP conjugated anti-human IgG (Southern Biotech: 1 in 25,000), IgA (Sigma: 1 in 6,000-
10,000), and IgM (Sigma: 1 in 3,000). SIGMAFASTTM OPD (o-phenylenediamine dihydrochloride) (Sigma-Aldrich) was used to
develop plates and reactions were stopped after 30 minutes with 3M HCl. Optical density was read at 492 nm (to measure signal)
and 620 nm (background) using a BMG FLUOstar OMEGA PlateReader with MARS Data Analysis software. The optical density
(OD) readings at 492 nm for each well were subtracted from the OD at 620 nm then corrected for the average signal of blank wells
from the same plate; ODs reported are an average of duplicate wells per sample.
Saliva ELISA
Salivary antibodies specific for SARS-CoV-2 spike protein were detected with an ELISA based on the methodology described above
with somemodifications. Antigens were diluted in PBS and MICROLON plates (Griener Bio-One) were coated with 10 mg/mL spike
protein overnight at 4C. Saliva was heat inactivated at 56C for 30 minutes and centrifuged at 13,000 g for 5 minutes to pellet debris.
Saliva supernatants were assayed singly, diluted at either 1 in 10 (IgA) or 1 in 5 (IgG) to a final volume of 100 mL per well. Secondary
antibodies were as described for serum with concentrations optimized for saliva: IgA at 1:20,000 and IgG at 1:15,000. Plates were
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developed with 1-StepUltra TMB-ELISA Substrate Solution (Thermo Fisher) for 20 minutes and the reaction was quenched with 2M
H2SO4 (Merck). All incubations were temperature controlled at 23C. ODs were read at 450 nm and 570 nm using the same reader.
Luciferase immunoprecipitation system (LIPS)
Detection and quantification of IgG specific to RBD was performed using an N-terminally nanoluciferase tagged monomeric RBD
construct with competitive displacement based on previously described methodology.20 To make the construct, modified coding
sequences were designed and obtained as synthetic genes (Eurofins Genomics) allowing production of secretory Nanoluciferase
n-terminally tagged RBD domain through subcloning of the antigen into modified pCMV-TnT (Promega) vectors. Recombinant nano-
luciferase-tagged antigen was expressed by transient transfection of the corresponding plasmid into Expi293F cells (Expi293
Expression System, Thermo Fisher Scientific) according to the manufacturer’s instructions. Recombinant protein was harvested af-
ter 48 hours from the supernatant and stored and shipped at 80C. The procedure for immunoassay was, briefly, samples (1 uL, 4
replicates) were incubated for 2 hours at RT with 4x106 (+/5%) luminescence units of N-terminally nanoluciferase tagged mono-
meric RBD construct diluted in 25 uL of buffer (20 mM Tris Buffer, 150mM NaCl, 0.5% Tween-20, pH 7.4 [TBST], and 0.05% casein
in label incubation buffer only) with or without addition of unlabelled RBD (8x108 mol/L). Immunocomplexes were precipitated using
2.5ml glycine-blocked Protein A Sepharose 4 fast flow (Cytiva) and 2.5ml ethanolamine-blocked Protein GSepharose (Cytiva) (washed
4 times in TBST) for 1hr with shaking (700rpm) as previously described.21 Precipitates were washed 5 times with TBST and then
transferred to a 96-well OptiplateTM (Perkin-Elmer) and excess buffer removed by aspiration (end volume 30 uL). Nano-Glo sub-
strate (40 mL, Promega) was injected into each well immediately before counting in a Hidex Sense Beta (Hidex). Raw data were con-
verted into units using a standard curve made by serially diluting a pool of positive samples in SARS-CoV-2 antibody negative human
AB serum (Merck KGaA).
Virus neutralisation assay
Heat inactivated serum samples (30 min at 56C) were serially diluted 2.5-fold, from a 1:20 starting dilution in duplicate in Minimum
Essential Media (Thermo Fisher Scientific) containing 2% FBS and NEAA for 8 dilutions. Control wells containing virus only (no sera)
as well as positive and negative control sera were also included on each plate. SARS-CoV-2 virus from the isolate SARS-CoV-2/hu-
man/Liverpool/REMRQ0001/2020 (gift fromDr. Lance Turtle, University of Liverpool) was grown on Vero-TMPRSS2 cells and titrated
as previously described.22 Virus was mixed with dilutions of the sera at a multiplicity of infection of 0.4 and incubated for 60 min at
37C. Following the incubation, supernatants were removed from the cells and virus:sera dilutions were added to Vero E6 cells
seeded previously in mClear 96 well microplates (Greiner Bio-One) and incubated for 18 hours at 37C in 5% CO2. Cells were fixed
by incubation in 4% PFA for 60 minutes followed by permeabilisation with Triton X-100 and blocking with BSA. Cells were stained
with DAPI (Sigma Aldridge) and an antibody against the SARS-CoV-2 nucleocapsid protein (200-401-A50, Rockland) in combination
with a corresponding fluorophore conjugated secondary antibody (Goat anti-Rabbit, AlexaFluor 568, Thermo Fisher Scientific). Im-
ages were acquired on the ImageXpress Pico Automated Cell Imaging System (Molecular Devices) using a 10X objective. Stitched
images of 9 fields covering the central 50% of the well were analyzed for infected cells using Cell ReporterXpress software (Molecular
Devices). Briefly, cell numbers were determined by automated counted of DAPI stained nuclei, infected cells were determined as
those cells in which positive nucleocapsid staining, associatedwith a nucleus, was detected. The percentage of infected cells relative
to control wells containing virus only (no sera) were calculated.
Synthetic peptides
15-mer peptides overlapping by ten amino acid residues and spanning the SARS-CoV-2 spike protein were either purchased from
Mimotopes (Australia) or donated by Prof Tao Dong (Oxford University). The purity of the peptides were > 80% or > 75%, respec-
tively. Peptides were dissolved as described previously.23 SARS-CoV-2 membrane and nucleocapsid Peptivator peptide pools
were purchased from Miltenyi Biotec.
ELISpot
Cryopreserved PBMCs were thawed and rested in a humidified incubator at 37C/5%CO2 for 5 hours. Human IFN-g ELISpot assays
were performed using Human IFN-g ELISpotPLUS Kit (MABTECH) according to manufacturer’s instructions. Pre-coated (mAb-D1K)
plates were washed four times in sterile PBS and blocked for 2-3 hours using R10 (RPMI/10% FCS) medium. Rested PBMC were
washed, counted, and resuspended in R2 (RPMI/2% FCS) medium; 2x105 PBMC were added to the plate with or without peptide
pools (see below) in a total assay volume of 100 mL. PBMC incubated with R2 medium alone were used as negative (unstimulated)
controls. PBMC stimulated with PMA at 1 mg/mL and ionomycin at 10 mg/mL (Sigma Aldrich), or anti-CD3 antibody (MABTECH, Mab
CD3-2, 0.1% v/v) were used as positive controls (1-2x105 PBMC per well). Antigen-specific cellular responses were measured
following stimulation with an overlapping peptide library spanning the entire spike protein (divided across two pools: S1 and S2)
(Mimotopes) at a final concentration of 2 mg/mL in R2. All assays were performed in duplicate. Plates were incubated for 18 hours
at 37C/5% CO2 in a humidified incubator. For development, plates were washed 5 times in PBS then incubated for 2 hours at
room temperature with detection antibody (7-B6-1-biotin; 1mg/mL) in reagent diluent (PBS/0.5% FCS). Following incubation, plates
were washed 5 times in PBS and incubated for 1 hour at room temperature with 0.1% v/v Streptavidin-ALP diluted in reagent diluent.
Developed plates were protected from light and dried for 24-48 hours before image acquisition using C.T.L. ImmunoSpot S6 Ultra-V
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Analyzer. All plates were read using the same settings. Spot forming units (SFU) permillion PBMCwere calculated after subtraction of
average background calculated from negative control wells.
Ex vivo stimulation, intracellular cytokine staining and flow cytometry
Cryopreserved PBMCwere thawed, washed and plated at 1x106 cells per well in AIM-Vmedium (Invitrogen) with 2%FCS in a 96-well
plate, and incubated for 5 hours at 37C/5%CO2 in the presence of brefeldin A at 5 mg/ml (BDBiosciences) with overlapping peptides
from the SARS-CoV-2 proteins spike (see above), membrane (Miltenyi Biotec) and nucleoprotein (Miltenyi Biotec) at 1 mg/ml final con-
centration, or PMA at 10 ng/mL and ionomycin at 100ng/mL (Sigma Aldrich), or unstimulated (media) control. Following incubation,
cells were stained with Zombie Live/Dead Aqua (BioLegend) for 10 min at room temperature before staining for surface markers for
20min at 4C, diluted in PBS (HyClone) 1%BSA (Sigma Aldrich) with an antibody cocktail containing anti-CD4 BV650, anti-CD8APC-
Cy7 and anti-CCR7 PE-Cy7 (BioLegend) as well as anti-CD3 AF700 and anti-CD45RA PE (BD Biosciences) antibodies. Cells were
then fixed for 45 min in eBioscience Foxp3/Transcription factor fixation/permeabilization buffer (Invitrogen) and intracellular staining
was performed for detection of intracellular cytokines [(anti-IFN-g V450, BD Biosciences), (anti-TNF-a PE/Dazzle 594, BioLegend)]
using eBioscience Foxp3/Transcription factor permeabilization buffer for Ki67 (Invitrogen) for 30 min on ice. Cells were acquired on a
BD Fortessa X20 cytometer. Single stain controls were prepared using compensation beads (OneComp, Thermo Fisher Scientific).
Samples were analyzed after compensation was set using FlowJo (Version 10.3, FlowJo LLC) and gating determined using the fluo-
rescence-minus-one principle. The frequency of cytokine positive cells following stimulation was calculated by subtracting the fre-
quency observed in a well containing cells without exogenous stimuli (i.e., media only) from a parallel well containing stimulated cells.
In vitro expansion of T cells with SARS-CoV-2 peptides
PBMCs were thawed and washed with PBS 1% BSA. 20% of cells were pulsed in AIM-V medium with 2% human serum (Merck
KGaA) with peptide pools from SARS-CoV-2 spike protein, membrane/nucleocapsid proteins at 5 mg/ml for 45 min at 37C 5%
CO2. After stimulation cells were washed in PBS 1% BSA and resuspended with remaining 80% of the PBMCs in AIM-V 2% human
serum with 20 IU/ml of IL-2 (R&D Systems) and cultured for 10 days in 96-well U well plates at 0.6x106 cells /well, as previously
described.24 After 10-day expansion culture, cells were re-stimulated for 5 hours with SARS-CoV-2 peptide pools (as described
above in ex vivo experiments) or unstimulated (media) control. The frequency of cytokine positive cells following re-stimulation
was calculated by subtracting the frequency observed in a well containing cells without exogenous re-stimulation (i.e., media
only) from a parallel well containing re-stimulated cells.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis and plots were produced using Prism (Version 9.0, GraphPad Software). Comparisons of the antibody/cellular
response between the infant and parent groups were made using the Mann Whitney U test. When the antibody/cellular responses
of infants were compared with more than one adult group, the significance was determined by the Kruskal-Wallis test with Bonfer-
roni’s correction for multiple comparisons. The Benjamini-Hochberg method was used to control for the False Discovery Rate (FDR)
of multiple assays being performed on the same sample. The significance levels were set at p < 0.05 and FDR < 0.05. To investigate
variation in immune responses of infants and parents, all features were reduced using principal component analysis (R statistical soft-
ware version 4.0.2; prcomp function). Data from all antibody and cellular assays were included and scaled. Missing values were
imputed with group means for family 1 saliva IgG/IgA and IFNg production by total PBMCs (ELISpot). Principal components were
visualized and 95% confidence ellipses plotted using the factoextra package (Version 1.0.7).
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